Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival

Kidney International

Volumn 85, Issue 1, 2014, Pages 182-190

  Serre, Jean Emmanuel ^a   Michonneau, David ^b   Bachy, Emmanuel ^c   Noël, Laure Hélène ^b   Dubois, Valérie ^a,d   Suberbielle, Caroline ^e   Kreis, Henri ^b,f   Legendre, Christophe ^b,f   Mamzer Bruneel, Marie Fra ^b,f   Morelon, Emmanuel ^a,c,g   Thaunat, Olivier ^a,c,g  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

^d ETABLISSEMENT FRANÇAIS DU SANG   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITÉ DE LYON   (France)

Author keywords

antibody mediated rejection; chronic allograft failure; chronic allograft rejection; immunosuppression; kidney transplantation

Indexed keywords

CALCINEURIN; HLA ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECIPIENT; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; INFANT; KIDNEY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84891556475     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.253     Document Type: Article

References (37)

1. Caillard S, Lamy FX, Quelen C et al. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant 2012; 12: 682-693.
2. Caillard S, Porcher R, Provot F et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol 2013; 31: 1302-1309.
3. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587. (Pubitemid 14156511)
4. Ho M, Miller G, Atchison RW et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985; 152: 876-886. (Pubitemid 16236674)
5. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350: 1328-1337. (Pubitemid 38375368)
6. Kutok JL, Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 2006; 1: 375-404.
7. Murukesan V, Mukherjee S. Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens. Drugs 2012; 72: 1631-1643.
8. Swinnen LJ, LeBlanc M, Grogan TM et al. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation 2008; 86: 215-222.
9. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088. (Pubitemid 32448822)
10. Reshef R, Vardhanabhuti S, Luskin MR et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar). Am J Transplant 2011; 11: 336-347.
11. Kasiske BL, Kukla A, Thomas D et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis 2011; 58: 971-980.
12. Parker A, Bowles K, Bradley JA et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol 2010; 149: 675-692.
13. Paya CV, Fung JJ, Nalesnik MA et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
14. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. 6.1 Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002; 17(Suppl 4): 31-33.
15. Guba M, Graeb C, Jauch KW et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77: 1777-1782. (Pubitemid 38822196)
16. Thaunat O, Morelon E. [Cancer and immunosuppression: pro- and antitumoral effects of immunosuppressive drugs]. Nephrol Ther 2005; 1: 23-30.
17. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717. (Pubitemid 36629155)
18. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Semin Immunol 2012; 24: 115-121.
19. Thaunat O. Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol 2012; 26: 101-106.
20. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012; 93: 751-756.
21. He X, Moore J, Shabir S et al. Comparison of the predictive performance of eGFR formulae for mortality and graft failure in renal transplant recipients. Transplantation 2009; 87: 384-392.
22. Mariat C, Maillard N, Phayphet M et al. Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand? Nephrol Dial Transplant 2008; 23: 33-38. (Pubitemid 351767426)
23. Daniel V, Opelz G. Clinical relevance of immune monitoring in solid organ transplantation. Int Rev Immunol 2009; 28: 155-184.
24. Barraclough KA, Staatz CE, Isbel NM et al. Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation. Nephrology (Carlton) 2010; 15: 522-532.
25. Herman M, Weinstein T, Korzets A et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14-20. (Pubitemid 32100171)
26. Andre N, Roquelaure B, Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses 2004; 63: 647-652. (Pubitemid 39485832)
27. Tanner JE, Menezes J. Interleukin-6 and Epstein-Barr virus induction by cyclosporine A: potential role in lymphoproliferative disease. Blood 1994; 84: 3956-3964. (Pubitemid 24362498)
28. Walz G, Zanker B, Melton LB et al. Possible association of the immunosuppressive and B cell lymphoma-promoting properties of cyclosporine. Transplantation 1990; 49: 191-194. (Pubitemid 20051614)
29. Penn I. Cancers following cyclosporine therapy. Transplant Proc 1987; 19: 2211-2213.
30. Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243. (Pubitemid 41746802)
31. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230. (Pubitemid 38248525)
32. Mamzer-Bruneel MF, Lome C, Morelon E et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 3622-3632.
33. Trappe R, Hinrichs C, Appel U et al. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression. Am J Transplant 2009; 9: 2331-2337.
34. Michonneau D, Suarez F, Lambert J et al. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrol Dial Transplant 2012; 28: 471-478.
35. Swerdlow S. WHO classification of post-transplant lymphoproliferative disorders. In: Swerdlow S, Campo E, Harris N eds). Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008; 342-349.
36. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
37. Sis B, Jhangri GS, Riopel J et al. A new diagnostic algorithm for antibodymediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168-1179.